Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAgostini, Lívia da Cunha-
Autor(es): dc.creatorSilva, Nayara Nascimento Toledo-
Autor(es): dc.creatorBelo, Vanessa de Almeida-
Autor(es): dc.creatorLuizon, Marcelo Rizzatti-
Autor(es): dc.creatorLima, Angélica Alves-
Autor(es): dc.creatorSilva, Glenda Nicioli da-
Data de aceite: dc.date.accessioned2025-08-21T15:36:11Z-
Data de disponibilização: dc.date.available2025-08-21T15:36:11Z-
Data de envio: dc.date.issued2025-02-03-
Data de envio: dc.date.issued2025-02-03-
Data de envio: dc.date.issued2023-
Fonte completa do material: dc.identifierhttps://www.repositorio.ufop.br/handle/123456789/19696-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S001429992400596X?via%3Dihub-
Fonte completa do material: dc.identifierhttps://doi.org/10.1016/j.ejphar.2024.176907-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1019477-
Descrição: dc.descriptionCardiovascular diseases (CVDs) have a high mortality rate, and despite the several available therapeutic targets, non-response to antihypertensives remains a common problem. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are important classes of drugs recommended as first-line therapy for several CVDs. However, response to ACEIs and ARBs varies among treated patients. Pharmacogenomics assesses how an individual’s genetic characteristics affect their likely response to drug therapy. Currently, numerous studies suggest that genetic polymorphisms may contribute to variability in drug response. Moreover, further studies evaluating gene-gene interactions within signaling pathways in response to antihypertensives might help to unravel potential genetic predictors for antihypertensive response. This review summarizes the pharmacogenetic data for ACEIs and ARBs in patients with CVD, and discusses the potential pharmacogenetics of these classes of antihypertensives in clinical practice. However, replication studies in different populations are needed. In addition, studies that evaluate gene-gene interactions that share signaling pathways in the response to antihypertensive drugs might facilitate the discovery of genetic predictors for antihypertensive response.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectAngiotensin-converting enzyme inhibitors-
Palavras-chave: dc.subjectAngiotensin II receptor blockers-
Palavras-chave: dc.subjectCardiovascular diseases-
Palavras-chave: dc.subjectHypertension-
Palavras-chave: dc.subjectPharmacogenetics-
Título: dc.titlePharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.